Department of Urology, Rush University, Chicago, IL 60612, USA.
Department of Urology, Sant'Andrea Hospital, La Sapienza University, 00189 Rome, Italy.
Curr Oncol. 2023 Apr 20;30(4):4301-4310. doi: 10.3390/curroncol30040328.
In 2018, the da Vinci Single Port (SP) robotic system was approved by the US Food and Drug Administration for urologic procedures. Available studies for the application of SP to prostate cancer surgery are limited. The aim of our study is to summarize the current evidence on the techniques and outcomes of SP robot-assisted radical prostatectomy (SP-RARLP) procedures. A narrative review of the literature was performed in January 2023. Preliminary results suggest that SP-RALP is safe and feasible, and it can offer comparable outcomes to the standard multiport RALP. Extraperitoneal and transvesical SP-RALP appear to be the two most promising approaches, as they offer decreased invasiveness, potentially shorter length of stay, and better pain control. Long-term, high-quality data are missing and further validation with prospective studies across different sites is required.
2018 年，达芬奇单端口（SP）机器人系统获得美国食品和药物管理局批准，可用于泌尿科手术。目前应用 SP 进行前列腺癌手术的研究有限。我们的研究旨在总结 SP 机器人辅助根治性前列腺切除术（SP-RARLP）的技术和结果。2023 年 1 月进行了文献的叙述性综述。初步结果表明，SP-RALP 安全可行，可提供与标准多端口 RALP 相当的结果。经腹腔外和经膀胱 SP-RALP 似乎是两种最有前途的方法，因为它们具有侵入性更小、潜在住院时间更短和更好的疼痛控制。目前缺乏长期、高质量的数据，需要在不同地点进行前瞻性研究来进一步验证。
